iCHOROSBreztri/Trixeo Outcomes in Moderate to Severe COPD

This study focuses on adults with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who are being treated with a medication called Breztri/Trixeo. COPD is a serious lung condition that makes it hard to breathe and often gets worse over time, leading to frequent hospital visits and a significant impact on quality of life, especially in countries with fewer healthcare resources. The study aims to gather real-world data on how well Breztri/Trixeo works outside of controlled clinical trials. This will involve understanding its effectiveness, safety, and the patient experience, which is crucial for improving treatment strategies and outcomes for those living with COPD across different parts of the world, including Latin America, Asia, and the Middle East. Participants in the study will use Breztri/Trixeo, which is an inhaler that delivers three medications to help manage COPD symptoms. The study will track changes in participants' health by measuring their scores on the COPD Assessment Test (CAT) after 12 weeks of treatment, with additional checks at 26 and 52 weeks. Other important measures will include the frequency of COPD flare-ups and patient satisfaction with the inhaler. The study will involve routine visits to the doctor, where information such as medical history and medication use will be collected. Doctors will decide on all treatments, ensuring that the study reflects typical real-world medical practice. The study will last for up to 52 weeks for each participant, providing valuable insights into how Breztri/Trixeo performs in everyday use.